Edwards Lifesciences, a provider in the science of heart valves and hemodynamic monitoring, has completed the acquisition of Embrella Cardiovascular, the developer of the Embrella Embolic Deflector System, for approximately $43m cash.

The Embrella Embolic Deflector System can be used during transcatheter heart valve procedures.

The single-use, disposable Embrella device is placed in the aorta through a sheath inserted in the right brachial or right radial artery and its porous membrane allows blood flow to the brain while simultaneously deflecting embolic material.

The Embrella Embolic Deflector System has been assessed in a limited clinical study in Europe and received CE mark there in May 2010.

Edwards Transcatheter Valve Replacement corporate vice president Larry Wood said the acquisition is consistent with dedication to the ongoing exploration and development of novel technologies that have the potential to improve outcomes for patients, and supports our strategy to extend Edwards’ global leadership in transcatheter heart valves.